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The rational design of synthetic peptides is proposed as an eﬃcient strategy for the structural investigation of crucial protein
domains diﬃcult to be produced. Only after half a century since the function of ACE was ﬁrst reported, was its crystal structure
solved. The main obstacle to be overcome for the determination of the high resolution structure was the crystallization of the
highly hydrophobic transmembrane domain. Following our previous work, synthetic peptides and Zinc(II) metal ions are used
to build structural maquettes of the two Zn-catalytic active sites of the ACE somatic isoform. Structural investigations of the
synthetic peptides, representing the two diﬀerent somatic isoform active sites, through circular dichroism and NMR experiments
are reported.
1.Introduction
Angiotensin Converting Enzyme (ACE) catalyses the conver-
sionofangiotensin-I(AI)tothevasoconstrictorangiotensin-
II (AII) [1] and inactivates the vasodilatory peptide
bradykininbyremovingC-terminaldipeptides[2].Theinhi-
bition of ACE enzymatic activity against AI was considered
as one of the major challenges against hypertensive disease
a n dc o n g e s t i v eh e a r tf a i l u r e[ 3]. Over the past 20 years,
ACE inhibitors have presented signiﬁcant cardioprotective
and vasculoprotective activity, by reducing oxidative stress
and inﬂammation in the endothelium. Moreover, ACE
inhibitors have been eﬀective in improving blood ﬂow and
ﬂow-mediated vasodilation. Inhibition of the angiotensin
converting enzyme signiﬁcantly reduces cardiovascular risk
in a broad range of high-risk patients [4, 5].
ACE is a Zinc Metallopeptidase and one of the major
components of the Renin-Angiotensin System (RAS) that
regulates blood pressure [6–8]. In human, ACE is expressed
as a somatic isoform in endothelial, epithelial, and neu-
roepithelial cells and as a smaller isoform only in male
germinal cells. Somatic ACE (1306AA, 150kDa) consists of
two homologous domains, one at each terminal, containing
zinc catalytic sites (N-and C-zinc catalytic sites) [9]. The
testis isoform is composed of 732 residues (83kDa) with
the 665-residue C-terminal domain being identical to the C-
terminaldomainofthesomaticform[10–13].Bothisoforms
possess a zinc-binding domain, with the somatic isoform
containing one additional high homology active site (N-
catalytic site). ACE active sites possess the characteristic
HEXXH Zn-binding motif (the two His comprise the ﬁrst
two Zn-ligands) and falls into the gluzincin family [14]. The
third Zn ligand, glutamic acid, is sited 23 residues towards
the enzyme C-terminal at the second characteristic sequence
EAXGD [15]. The fourth zinc ligand is a water molecule.
In subsequent to our previous work [16, 17], novel
synthetic peptides have been investigated as structural
maquettes, in order to shed further light on the conforma-
tional characteristics of both somatic isoform catalytic site
domains.
Design, peptide synthesis, and a thorough investigation
of the optimal conditions in order to mimic as closely2 Bioinorganic Chemistry and Applications
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Figure 1:SyntheticpeptidemaquettesoftheN-andC-activesitedomainsofhumansomaticACE(sACE).Sequencenumberingofpeptides,
sACE, testis isoform (tACE) and crystal structures domains. The diﬀerent residues among the two sequences are highlighted.
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Figure 2: (a) Short-, medium-, and long-range connectivities. (b) Number of NOE constraints per residue (white, gray, dark gray, and black
vertical bars represent, resp., intraresidue, sequential, medium-range and long-range connectivities). (c) Schematic representation of the
sequential and medium range NOEs involving HN, Hα, and Hβ protons for Zn2+-ACEN(37) (corresponds to His360-Ala396 of the human
somatic form).
as possible the structure of the enzyme native active sites
are reported. The peptide structures have been determined
through circular dichroism and NMR experiments.
The conformational diﬀerences of the peptide maquettes
representing the two sACE active sites have been also
investigated. Moreover, the NMR solution structures of the
peptides are being compared to the crystal structure of
somatic ACEN active site [18] and the testis ACE isoform
(tACE) [19] that corresponds to the somatic ACEC domain.
In general, we report herein a work, which exploits the
potential of peptide chemistry to synthesize polypeptides
that represent protein domains or functional fragments and
applies a step-by-step investigation strategy able to extract
crucial structural data, especially for the metal active sites
of enzymes/proteins or others biopolymers, whose biological
expression and crystallization are diﬃcult to be acquired,
such as GPCRs and highly hydrophobic transmembrane
proteins.Bioinorganic Chemistry and Applications 3
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Figure 3: (a) Short-, medium-, and long-range connectivities. (b) Number of NOE constraints per residue (white, gray, dark gray, and black
vertical bars represent, resp., intraresidue, sequential, medium-range, and long-range connectivities). (c) Schematic representation of the
sequential and medium range NOEs involving HN, Hα, and Hβ protons for Zn2+-ACEC(37) (corresponds to His958-Ala994 of the human
somatic form).
2.MaterialsandMethods
2.1. Peptide Synthesis. Both peptides representing the
domains of the two somatic ACE (sACE) active sites
ACEN(37):sACE(360–396); ACEC(37):sACE(958–994) were
synthesized on solid support by Fmoc/tBu chemistry, as
previously described [15]. Sequence enumeration of the
synthetic peptides and the corresponding domains of the
human somatic isoform as well as the numbering of the C-
(tACE) and N-domain (ACEN) crystal structures are shown
in Figure 1.
2.2. Circular Dichroism Experiments. CD experiments were
acquired for both ACEN(37) and ACEC(37) peptides, mon-
itoring the eﬀect of diﬀerent triﬂuoroethanol (TFE) con-
centration, pH values, and Zn+2 addition on their con-
formations. Spectra were recorded on a Jasco 710 spec-
tropolarimeter using quartz cells of 1.0cm and 0.5cm path
length, in the far-UV (200nm–260nm) at a scanning rate of
100nm/min,atimeconstantof1s,andabandwidthof1nm.
Spectralresolutionwas0.2nm,and4scanswereaveragedper
spectrum.
The concentration used for each sample was 0.3–
0.35mg/ml of pure peptide in a buﬀer of 50mM Tris-HCl
and 200mM NaCl. The eﬀect of TFE on the peptide
conformation wasmonitored for 0%–100% TFE (v/v),25
◦C,
and pH = 7.0. Spectra of diﬀe r e n tp Hv a l u e sr a n g i n gf r o m
2.6 to 7.0 were recorded for the Zn-containing ACEN(37)
peptide, at 65% TFE and 25
◦C. Quantitative evaluation of
secondary structure according to the CD data was calcu-
lated using the CDNN CD Spectra Deconvolution Program
obtained from http://bioinformatik.biochemtech.unihalle
.de/cdnn/ [20] .T h eC Ds p e c t r aa r er e p o r t e di nm o l a r
ellipticity as mdeg × cm2/dmol according to molecular
masses and peptide length.
2.3. Nuclear Magnetic Resonance Experiments. 5mgofpep-
tide samples were dissolved in a mixture of 65% TFE in
H2O,containing50mMTrisbuﬀerand200mMNaCl.ZnCl2
was added in a slight excess of the peptide equivalents
(1:1.1) until 0.5ml ﬁnal sample volume, with the peptide
concentration being approximately 2mM at pH value 4.9–
5.1.
Datawereacquiredat298KonaBrukerAvance600MHz
spectrometer. 1H 1D NMR spectra were recorded using
spectral width of 12–17ppm with or without presaturation
of the H2O signal. 1H-1H2 DT O C S Y[ 21, 22]w e r er e c o r d e d
using the MLEV-17 spin lock sequence using τm = 80ms.4 Bioinorganic Chemistry and Applications
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Figure 4: Circular dichroism spectra (left) and corresponding diagrams (right) of helical content through data analysis by CDNN software
of (a) 2,2,2-triﬂuoroethanol (TFE) range from 0% to 100% of Zn2+-ACEN(37) samples, at pH = 5.0, T = 25
◦C, 50mM Tris-HCl, and
200mM NaCl and (b) of pH range from 2.6 to 7 of Zn2+-ACEN(37) samples, at 65% TFE, T = 25
◦C, 50mM Tris-HCl, and 200mM NaCl.
15NH S Q Ca n d13CH S Q Cs p e c t r a[ 23, 24]h a v eb e e n
recorded at 500MHz equipped with cryoprobe for 15N/13C
nuclei in natural abundance. 1H-1H TPPI NOESY [25, 26]
spectra were acquired using mixing time τm = 200ms
applying water suppression during the relaxation delay and
mixing time. For data processing and spectral analysis, the
standard Bruker software (XWIN-NMR 3.5) and XEASY
program [27]( E T H ,Z u r i c h )w e r eu s e d .
1318 and 1578 NOESY cross-peaks were assigned in
both dimensions for ACEC(37), and ACEN(37), respectively,
in TFE aqueous solution (TFE/H202 : 1 ) .T h en u m b e ro f
unique cross-peaks was 753 and 773 for ACEC(37) and
ACEN(37), respectively. Their intensities were converted into
upper limit distances through CALIBA [28]. The NOE-
derived structural information extracted from the analysis
of NOESY spectra acquired in aqueous TFE solutions
under identical experimental conditions for both peptides
were introduced to DYANA [29, 30] software for structure
calculation (Figures 2 and 3). Structural calculations have
been performed on IBM RISC6000 and xw4100/xw4200HP
Linux workstations. The family ensemble of Zn2+-ACEN(37)
peptide presents root mean square deviation (RMSD) values
of 0.65 ± 0.21 ˚ A and 1.25 ± 0.24 ˚ A for backbone and heavy
atoms, respectively, and the average target function was
foundtobe0.39 ± 0.0164 ˚ A2.TheRMSDvaluesoftheZn2+-
ACEC(37) peptide were 0.55 ± 0.23 ˚ A and 1.04 ± 0.27 ˚ Af o r
backbone and heavy atoms, respectively, and target function
lies in the range 0.60 ± 4.78 × 10−2 ˚ A2.Bioinorganic Chemistry and Applications 5
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Figure 5: Fingerprint regions of 600MHz TOCSY ((a) ACEC(37) and (b) ACEN(37)) and NOESY ((c) ACEC(37) and (d) ACEN(37))spectra
recorded at T = 298K. The sequential connectivity pattern shown indicates the peptide sequence-speciﬁc resonance assignment.
3. Results andDiscussion
3.1. α-Helix Content Measurements through Circular Dichro-
ism Data. The Circular Dichroism (CD) experiments pro-
vided a qualitative determination of the peptide secondary
structure elements in diﬀerent TFE concentrations, pH
values, and metal addition, leading to the determination of
high resolution experimental conditions (Figure 4).
Speciﬁcally, the Zn2+-ACEN(37) peptide presents an
unfolded structure with low α-helical content in aqueous
solution. Low TFE concentrations (up to 20%) do not
seem to have major eﬀect on the peptide conformation
(Figure 4(a)). However, the CD spectrum of the sample
containing 35% TFE shows two intense minima at 208
and 220nm, characteristics of α-helical structure. Thus,
for TFE concentration ranging from 20% to 35%, an
abrupt structural change takes place, leading to a dramatical
increase of α-helix content from 26% to 52%. At higher
TFE concentrations (50%–100%), no remarkable alteration
of the helical content is noticed. In more detail, the α-
helical content is increased from 54% to 60%, for TFE
concentration increasing from 50% to 100%, indicating
secondary structure stability of the Zn2+-ACEN(37) peptide
at alcohol concentration greater than 50%. Similar results
were obtained for the Zn2+-ACEC(37) peptide (data not
shown). As a conclusion, the synthetic peptides exhibit a
remarkable tendency to adopt helical conformation.
In order to investigate the pH eﬀect on the α-helical
content of the Zn2+-ACEN(37) peptide, CD measurements
were performed in 65% of TFE at 25
◦C, at acidic, low acidic,
and neutral pH values. Spectra representing two sets of pH
values nearly overlap, thus suggesting that the secondary
structure of ACE peptides exhibit minor diﬀerences at these
pH values (Figure 4(b)). In particular, at acidic (pH 2.6)
and mild acidic (pH 4.0) conditions, the Zn-containing
ACEN(37) solutions possess approximately 48% α-helical
content while at pH values of 5.0 and 7.0, the helicity of
the ACEN(37) in the presence of Zn2+ ions is found to be
approximately 57.0%.
3.2. NMR Spectra Assignment of Zn2+-ACEN(37)a n dZ n 2+-
ACEC(37) Peptides. Thirty-six out of 37 residues of the6 Bioinorganic Chemistry and Applications
Table 1: 1H, 15N, and 13C chemical shifts (ppm) of the residues in the Zn2+-ACEN(37) peptide at 298K (H2O/TFE-d2 34%/66% v/v. pH =
4.9).
Residue HN/N Hα/Cα Hβ/Cβ Other
1H i s 4.45 Hδ2 7.30; Hε18.44
55.39 Cδ 120.02 Cε1 139.44
2H i s 7.99 4.84 3.38/3.29 Hδ2 7.32; Hε18 . 4 5
N117.01 55.84 28.45 Cδ2 120.05 Cε1 137.64
3G l u 8.45 4.47 2.15/2.14 γCH3 2.65/2.62
N121.15 56.81 31.91 Cγ 31.90
4M e t 4.35 2.13/2.09 Hγ 2.49/2.44
57.51 33.70 Cγ 34.78
5G l y 8.22 3.98
N109.59 45.79
6H i s 8.22 4.72 3.41/3.39 Hδ2 7.26; Hε18 . 5 0
N. 119.31 57.08 28.57 Cδ 119.93 Cε1 136.27
7I l e 8.11 4.05 2.07 Hγ 1.70/1.32; γCH3 1.03 δCH3 0.98
N122.73 64.30 38.04 Cγ1 28.30 Cγ216.79 Cδ 12.22
8G l n 8.47 4.03 2.14/2.11 Hγ 2.44; δNH2 6.55/7.14
N120.70 59.13 28.91 Cγ 33.65 Nε2110.97
9T y r 7.84 4.26 3.12 Hδ 6.96; Hε 6.75;
N120.77 60.88 38.03 Cδ1133.66 Cε1 117.77
10 Tyr 7.87 4.29 3.26/3.22 Hδ 7.19; Hε 6.89;
N 120.23. 60.82 38.11 Cδ1132.73 Cε1 117.87
11 Leu 8.34 4.04 1.99/1.91 Hγ 1.53; δCH3 0.94
N119.99 57.26 41.69 Cγ 28.36 Cδ 21.77/24.48
12 Gln 7.81 4.11 2.01/1.91 Hγ 2.24/2.16; δNH2 6.42/6.99
N118.28 57.58 28.81 Cγ 33.54 Nε2 110.97
13 Tyr 7.91 4.38 3.10/2.82 Hδ 7.00; Hε 6.76
N120.43 59.51 35.59 Cδ1132.82 Cε1117.83
14 Lys 7.90 4.06 1.82/1.79 Hγ 1.39; δCH3 1.63; εCH3 3.03
N120.21 57.55 31.61 Cγ 23.71 Cδ 28.57 Cε 42.06
15 Asp 7.93 4.80 2.92/2.76
N 118.92 53.56 39.48
16 Leu 7.76 4.54 1.79 Hγ1.58; δCH3 0.94/0.94
123.89 54.95 41.64 Cγ 28.43 Cδ 23.05/24.36
17 Pro 4.45 2.39/1.95 Hγ 2.02/1.97; Hδ 3.88/3.64
63.27 31.32 Cγ 26.69 Cδ 50.27
18 Val 7.74 3.79 2.17 γCH3 1.06/1.01
N120.40 65.07 31.81 Cγ 20.89/20.12
19 Ser 8.02 4.23 3.99/3.95
N116.85 60.48
20 Leu 7.82 4.36 1.77 Hγ 1.68; δCH3 0.94/0.89
N122.93 56.20 41.96 Cγ 28.50 Cδ 22.29/24.73
21 Arg 7.77 4.20 1.93 Hγ 1.76/1.65; Hδ 3.20; Hε 7.05
N120.34 57.49 30.15 Cγ 26.99 Cδ 43.13 Nε 135.56
22 Arg 8.05 4.28 1.89/1.85 Hγ 1.75/1.64; Hδ 3.17; Hε 7.15
N121.00 57.05 30.14 Cγ 26.92 Cδ 43.07 Nε 135.62
23 Gly 8.00 3.95
N109.07 45.43
24 Ala 7.81 4.39 1.43
N124.37 52.21 19.05
25 Asn 7.98 5.02 2.96/2.79 δNH2 6.63/7.47
N119.26 51.13 39.17 Nδ2113.31
26 Pro 4.44 2.32/1.98 Hγ 2.07/2.00; Hδ 3.92/3.83
61.79 29.10 Cγ 26.76 Cδ 50.28Bioinorganic Chemistry and Applications 7
Table 1: Continued.
Residue HN/N Hα/Cα Hβ/Cβ Other
27 Gly 8.34 3.94
N 108.58 43.10
28 Phe 7.83 4.50 3.15/3.13 Hδ 7.25; Hε 7.29; Hζ 7.18
N122.56 56.50 36.59 Cδ 130.90/129.60 Cε 130.95/129.53 Cζ 131.21
29 His 8.05 4.44 3.32/3.25 Hδ2 7.31; Hε18 . 5 1
N119.37 54.41 25.86 Cδ2 119.91 Cε1 139.03
30 Glu 8.15 4.23 2.15/2.10 γCH3 2.45
N121.57 54.73 24.95 Cγ 33.54
31 Ala 8.07 4.31 1.46
N125.19 51.07 15.87
32 Ile 7.76 4.06 1.83 Hγ 1.44/1.18; γCH3 0.88; δCH3 0.82
N118.79 61.44 35.60 Cγ1 27.34 Cγ2 16.84 Cδ 12.08
33 Gly 7.96 3.95/3.87
N110.69 43.26
34 Asp 7.97 4.74 2.89
N120.70 51.72 36.82
35 Val 7.78 4.08 2.23 γCH3 1.00
N120.34 60.78 29.97 Cγ 20.31/24.50
36 Leu 7.82 4.40 1.72 Hγ 1.38; δCH3 0.92/0.88
N122.65 52.58 39.65 Cγ 27.26 Cδ 24.16/22.01
37 Ala 7.56 4.25 1.43
N128.06 50.34 16.51
backbone of both Zn2+-ACE peptides have been identiﬁed
through the analysis of the TOCSY spectra (Figure 5). 1H
spin systems of the His, Phe and Tyr aromatic rings were
identiﬁed with the combined use of [1H- 1H]- TOCSY
and NOESY spectra (Tables 1 and 2). The two proline
residues existing in each construct were found to be at
trans conformation for both peptides manifested by strong
Hδ(i)Pro- Hα(i-1) NOE connectivities.
3.3. NMR Solution Models of Zn2+-ACEN(37) & Zn2+-
ACEC(37) Peptides. As far as the N-terminal Zn-binding
motif of ACEN(37) peptide, which contains the two histidyl
ligands, is concerned, no deﬁnite conformation could be
determined due to conformational averaging. A 7-residue
fragment close to the N-terminal (Gln8-Asp15)a d o p t sh e l i c a l
structure, which consists partly of an α-helix for the 8-
11 fragment and of a short 310-helix for the rest of the
four-residue segment. A second fragment comprised of 7
residues close to peptide C-terminal (His29-L e u 36)a d o p t s
aw e l lf o r m e dα-helical structure. As far as the intermediate
fragment of the 23-residue spacer between the two binding
motifs is concerned, no helical conformation has been
identiﬁed. The proximity of the two “active sites helices” is
manifested by long-range NOEs concerning backbone and
side-chain protons of His2–Glu30,G l y 5–Gly34,T y r 9–Phe28
see(Figure S1)inSupplementaryMaterialavailableonlineat
doi: 10.1155/2010/820476, as well as Tyr9–His30 (Figure 6).
The Zn2+-ACEC(37) backbone is characterized by the
high content of helical structure. Two helical conformations
were observed at both N- and C-termini, spanning residues
His6–Lys14 and Phe28–Val35,r e s p e c t i v e l y .M o r e o v e r ,a3 10-
helix comprised of a 5-residue segment (Ala19-Gly23)h a s
been identiﬁed for the intermediate fragment. In accordance
with the Zn2+-ACEN(37) peptide, the two zinc-binding
motifs of Zn2+-ACEC(37) are in spatial proximity as mani-
fested by long-range NOEs, such as those between His6/Ile7
and His29 as well as Gln8/Gln12 with Ala19 (Figure 7).
3.4. Solution Structure of Zn2+-ACEN(37)v e r s u sZ n 2+-
ACEC(37). Although the overall fold of the two Zn2+-
ACE peptides exhibits signiﬁcant similarities, some striking
diﬀerences, mainly related to the helical extent are detected
(Figure 8) .T h ed o u b l es u b s t i t u t i o no fT y r 10 and Leu11 in
ACEN(37) with Phe10 and Met11 in ACEC(37) does not
impose any structural change, and the α-helix conformation
of this segment remains. The nonhelical character of the
N-terminal pentapeptide, which comprises the ﬁrst Zn2+-
binding motif, followed by a helical domain of eight to nine
residues is conserved in both ACE peptides. However, small
diﬀerences in NOEs are observed, regarding residues Ile7,
Phe10/Tyr10,a n dL e u 11/Met11 in ACEN(37) and ACEC(37)
peptide, respectively. Because of the diﬀerentiation in posi-
tion 10, the long range NOEs of the vicinal Tyr9 with
Phe28 and His29 that are presented in ACEN(37) peptide,
are not detected in ACEC(37). Furthermore, a long-range
NOE between Hε of Arg21 and Hε of Phe28 detected only in
Zn2+-ACEN(37) peptide suggests the existence of a loop with
the two residues coming close to each other, conﬁrming a
tertiary slight structural diﬀerence among the two peptides
in terms of the orientation of the two zinc-binding motif8 Bioinorganic Chemistry and Applications
Table 2: 1H, 15N, and 13C chemical shifts (ppm) of the residues in the Zn2+-ACEC(37) peptide at 298K (H2O/TFE-d2 34%/66% v/v. pH =
4.9).
Residue HN/N Hα/Cα Hβ/Cβ Other
1H i s 4.44 Hδ2 7.34; Hε18 . 4 8
55.45 Cδ2 120.14 Cε1 141.76
2H i s 7.92 4.83 3.41/3.37 Hδ27.31; Hε18.42
N 117.71 55.86 28.53 Cδ2 119.85 Cε1136.29
3G l u 8.44 4.47 2.15 γCH3 2.64
N 121.00 56.93 31.82 Cγ 31.95
4M e t 4.30 2.12/2.06 Hγ 2.44;
58.52 33.59 Cγ 34.85
5G l y 8.22 3.98
N 109.22 45.83
6H i s 8.22 4.69 3.39 Hδ27.25; Hε18 . 5 0
N.119.42 57.33 28.64 Cδ2119.79 Cε1138.23
7I l e 8.06 4.04 2.07 Hγ 1.71/1.31; γCH3 1.03 δCH3 0.97
N 122.46 64.13 38.09 Cγ1 28.41 Cγ216.81 Cδ 12.18
8G l n 8.44 4.08 2.15/2.11 Hγ 2.42; δNH2 6.54/7.13
N 121.01 59.04 28.57 Cγ 33.52 Nε2110.83
9T y r 7.90 4.27 3.12 Hδ 6.95; Hε 6.76
N 120.96 61.02 38.21 Cδ1132.67 Cε1117.74
10 Phe 8.07 4.37 3.33/3.26 Hδ 7.31; Hε 7.37 Hζ 7.34
N 120.42 60.74 38.84 Cδ 131.03/129.50 Cε 131.00/129.43 Cζ 131.36
11 Met 8.43 4.21 2.23/2.15 Hγ 2.79/2.72
N 118.65 57.43 33.58 Cγ 32.35
12 Gln 7.81 4.14 2.00/1.90 Hγ 2.22/2.17; δNH2 6.40/6.70
N 118.68 57.74 28.75 Cγ 33.50 Nε2 110.86
13 Tyr 7.92 4.38 3.13/2.82 Hδ 7.00; Hε 6.74
N 120.02 59.46 39.33 Cδ 132.81 Cε 117.84
14 Lys 7.85 4.05 1.78/1.81 Hγ 1.39; δCH3 1.64; εCH3 3.05
N 120.09 57.76 31.58 Cγ 23.68 Cδ 28.76 Cε 42.19
15 Asp 7.90 4.83 2.93/2.77
N 118.79 53.53 39.51
16 Leu 7.78 4.46 1.79 Hγ 1.77; δCH3 0.943/0.97
123.98 56.77 41.25 Cγ 26.83 Cδ 23.25/24.05
17 Pro 4.39 2.41/1.89 Hγ 2.11/2.07; Hδ 3.66/3.87
64.61 31.21 Cγ 26.79 Cδ 50.16
18 Val 7.60 3.68 2.17 γCH3 1.07/0.98
N 120.40 65.47 31.77 Cγ 20.23/21.25
19 Ala 7.94 4.08 1.46
N 123.38 54.68 18.08
20 Leu 7.95 4.25 1.78 Hγ 1.63; δCH3 0.92/0.89
N 123.48 56.69 41.91 Cγ 27.43 Cδ 22.06/24.33
21 Arg 7.70 4.15 1.96 Hγ 1.75/1.63; Hδ 3.15; Hε 7.06
N 120.14 57.82 30.09 Cγ 26.80 Cδ 42.96 Nε 135.38
22 Glu 8.23 4.30 2.10/2.00 γCH3 2.46/2.42
N 119.39 57.01 28.25 Cγ 33.01
23 Gly 7.95 3.93
N108.22. 45.70
24 Ala 7.78 4.40 1.45
N 123.97 52.25 18.47
25 Asn 7.90 5.03 3.03/2.81 δNH2 6.61/7.50
N 118.78 51.01 39.09 Nδ2 113.04Bioinorganic Chemistry and Applications 9
Table 2: Continued.
Residue HN/N Hα/Cα Hβ/Cβ Other
26 Pro 4.45 2.35/2.01 Hγ 2.07/2.02; Hδ 3.91/3.85
64.33 31.50 Cγ 26.84 Cδ 50.43
27 Gly 8.34 3.94
N 108.27 45.73
28 Phe 7.83 4.49 3.16 Hδ 7.24; Hε 7.28; Hζ 7.15
N 122.54 59.19 39.20 Cδ 130.90/129.43 Cε 130.94/129.55 Cζ 131.15
29 His 8.03 4.40 3.32/3.28 Hδ2 7.33; Hε18 . 5 1
N 118.86 57.20 28.38 Cδ2 119.94 Cε1 135.99
30 Glu 8.15 4.22 2.16/2.12 γCH3 2.46
N 121.32 57.33 27.91 Cγ 33.66
31 Ala 8.05 4.28 1.47
N 124.86 53.62 18.02
32 Ile 7.75 4.05 1.89 Hγ 1.41/1.18; γCH3 0.85; δCH3 0.80
N 118.32 64.06 38.03 Cγ1 27.29 Cγ2 16.80 Cδ 12.02
33 Gly 7.94 3.90/3.86
N 110.35 45.81
34 Asp 7.97 4.74 2.88
N 120.63 54.30 39.45
35 Val 7.77 4.08 2.24 γCH3 0.99
N 120.04 63.48 32.45 Cγ 20.23/23.01
36 Leu 7.83 4.39 1.71 Hγ 1.63; δCH3 0.92/0.88
N 125.55 55.14 42.14 Cγ 28.74 Cδ 24.36/21.98
37 Ala 7.55 4.24 1.43
N 128.05 52.89 19.23
N-terminal
C-terminal
(a)
N-terminal
C-terminal
(b)
Figure 6: (a) Ensemble of DYANA 30 best models of the Zn2+-ACEN(37) (corresponds to His360-Ala396 of the human somatic form)
calculated with NMR data. (b) Ribbon diagram of Zn2+-ACEN(37) peptide.
C-terminal
N-terminal
(a)
C-terminal
N-terminal
(b)
Figure 7: (a) Ensemble of DYANA 30 best models of the Zn2+-ACEC(37) (corresponds to His958-A l a 994of the human somatic form),
calculated with NMR data. (b) Ribbon diagram of Zn2+-ACEC(37) peptide.10 Bioinorganic Chemistry and Applications
N-terminal C-terminal
Zn2+-ACEN 37
(a)
N-terminal
C-terminal
Zn2+-ACEC 37
(b)
Figure 8: Backbone and ribbon representation of the solution structures of both Zn2+-ACEN(37) (a) (corresponds to His360-Ala396 of the
human somatic form) and Zn2+-ACEC(37) (b) (corresponds to His958-A l a 994of the human somatic form).
N-terminal
C-terminal
Crystal structure
Zn2+-ACEN-37
NMR structure
(a)
N-terminal
C-terminal
NMR structure
Zn2+-ACEC-37
Crystal structure
(b)
Figure 9: Superimposition of the crystal structure (in red) and the solution structure derived from NMR data (in cyan) of Zn2+-ACEN(37)
peptide (a) and Zn2+-ACEC(37) peptide (b).
helices. In ACEC(37) peptide, the two side chains of these
residues are oriented almost parallel to each other pointing
though to opposite orientation providing a more “extended”
conformation for this segment. Additionally, a helix of the
C-termini is observed in both peptides.
The substitutions of the amino acids at positions 19
(Ser19/Ala19)a n d2 2( A r g 22/Glu22) of the peptide sequence
seem to diﬀerentiate the structure of the two peptides.
The most important diversity among the structures of the
ACEN/C peptides regards the 5-residue spanning α-helix
(Ala19-Gly23) of the intermediate spacer between the two
zinc-binding motifs, detected only in the ACEC(37) peptide.
The absence of the intermediate helix in the ACEN(37)
peptide probably provides a less constrained domain to theBioinorganic Chemistry and Applications 11
N-active site of the somatic form in a crucial socket region
for the substrate binding. As a conclusion, the presence or
absence of the helical structure of the intermediate spacer
determines the relative position of the two terminal helices
and diﬀerentiates the active-site cavity structure and volume,
where the substrate is accommodated. Both active sites of
the somatic form act as carboxy dipeptidase, hydrolyzing the
amide bond and releasing the C-terminal dipeptide from a
native substrate [1]. Additionally, only the ACEN domain
presents endopeptidase activity, by releasing the C-terminal
tripeptide of the GnRH hormone and the tetrapeptide of
the native octapeptide Enkephalin [12]. Accommodation of
these peptides in active or not mode for proteolytic cleavage,
might be inﬂuenced by the conformation of the interhelical
spacer.
3.5. NMR Solution Structure versus X-Ray. The overall
fold of both synthetic peptides solution structures presents
high similarity to the corresponding domain of the crystal
structure of the testis ACE isoform [19] (tACE has identical
sequence with the C-domain of the ACE somatic isoform)
and the somatic ACEN domain [18]. Minor diﬀerences exist
regarding the length of the helices at the termini of the
peptides (Figure 9). The backbone RMSD value for the
family of 20 NMR structures of the ACEN peptide and the
crystal structure (2C6F) was found to be 1.42 ˚ A and the
corresponding RMSD value calculated for the mean NMR
structure and the X-ray structure was found to be 3.802 ˚ A.
The backbone RMSD value for the family of 20 NMR
structures of the ACEC peptide and the crystal structure
(1O8A) was found to be 0.775 ˚ A and the corresponding
RMSD value calculated for the mean NMR structure and the
X-ray structure was found to be 3.595 ˚ A.
In the tACE X-ray structure, two helical fragments are
present at the N- and C- terminal, both comprising a 12-
residue segment (Figure 9). For ACEN crystal structure the
N-terminal 13-residue fragment exhibits a helical conforma-
tion, as well as the entire C-terminal 12-residue fragment
(Figure 9(a)). Regarding the intermediate spacer among
the two zinc-binding motifs, an additional helix region
consistingof3aminoacidsispresentatbothtACEandACEN
X-ray structures. In the case of the NMR derived structure, a
shorter helical fragment has been observed for both termini.
The obtained data for the Zn2+-ACEN(37) suggest that as
f a ra st h eN - t e r m i n a li sc o n c e r n e da1 0 - r e s i d u ef r a g m e n t
(His6-Asp15) and as far as the C-terminal is concerned a 8-
residue fragment (His29-Leu36) exhibit helical conformation.
Similar results have been obtained for the synthetic peptide
representing the C-catalytic domain of the human somatic
form and the corresponding domain of the testis form.
Diﬀerences among the ACE catalytic site maquettes and X-
ray structures might be due to the fact that the native N-
and C-domains exhibit compact structures, and packing of
the structure elements in the interior of the enzyme where
the catalytic center is cited diminishes the conformational
ﬂexibility of the two active-site helices.
Concerning the intermediate spacer between the two
zinc-binging motifs, the X-ray models present an additive
3-residue helical segment residue, concerning residues 18-
20 (numbering of crystal structure: tACE: Val399-Leu401;
ACEN:V a l 377-Leu379). NMR solution structure of the Zn2+-
ACEC(37) peptide resulted in signiﬁcantly similar con-
formation. At ACEC(37) peptide, a 310 helix is formed
for the 5-residue segment Ala19-Gly23. Instead, no helical
conformation has been detected for the Zn2+-ACEN(37)
peptide, according to the NMR data and the DYANA
calculations. However, both structures of tACE and sACEN
have been further solved in complex with the typical
ACE inhibitor, lisinopril [19] (Figures S2 and S3). Among
them, a helical structure is identiﬁed for the intermediate
spacer only in the tACE-lisinopril structure, while in the
sACEN-lisinopril model the helical segment is absent. The
modiﬁcations of positions 19 and 22 in the sACEN peptide
are probably playing an important role in the structural
diversity of the spacer and are consequently crucial for the
diﬀerent activity and substrate speciﬁcity of these two active
sites.
As a conclusion, the conformation of the synthetic
peptides and the orientation of the two helical motifs
upon zinc coordination are remarkably similar to the native
structure, indicating the ACE catalytic site maquettes as
reliable models of the enzyme active centre. The detected
diﬀerences are clearly depended on the physicochemical
properties of the peptides in solution compared tothe crystal
structures.
4. Conclusions
NMR studies of the synthetic peptides generated structures
that successfully simulate the crystal structures of ACE C-
and N-domains. Circular dichroism experiments provided
important data, compensate not only for experimental
conditions of the NMR analysis, but also for the elucida-
tion of the structural characteristics of the two peptides,
corresponding to the two somatic isoform ACE catalytic
sites domains. The TFE use in aqueous mixtures, the
proper pH value, as well as the presence of the Zn-ion
create a solution environment, in which peptides adopt a
similar fold to the native structure. The NMR data and
the computational analysis led to structural models of the
peptides, which are in great agreement with the X-ray
structures. The secondary structure features of the peptides
that correspond to the sequence of the ACE catalytic sites
X-ray structures Zn2+-ACEN(37) to ACEN;Z n 2+-ACEC(37)
to tACE present minor diﬀerences compared to the crystal
structures. Furthermore, the ACE maquettes and the X-ray
structures present signiﬁcant similarities in the orientation
of the active site helices, in respect of the position of the
zinc ligands for metal coordination. On the other hand, the
peptide representing the N-catalytic site lacks the helix of the
intermediate region. Thus, the two terminal helices of the C-
catalytic site maquette are found closer than those in ACEN,
illustrating potential diﬀerences into the catalytic site pocket
for substrate selectivity, binding, and accommodation. This
crucial diﬀerence might possibly explain the functional
diversity of the two somatic isoforms of the human ACE.
This approach might be helpful in the reconstitution of12 Bioinorganic Chemistry and Applications
other enzymes’ active sites with unknown structures. In
gluzincins, the spacer among the two zinc-binding motifs
is regarded as of great importance for the speciﬁcity of the
native substrates and external ligands, such as inhibitors. As
far as somatic ACE is concerned, both active sites exhibit
carboxy dipeptidase function while only the N-catalytic site
exhibits also endopeptidase activity.
In the work reported here, crucial structural data for
solution conformations have been extracted even though
the crystal structure of testis ACE has been solved. Due
to the functional diversity of the two ACE active sites,
the “structure-based drug design” of the next generation
of pharmaceutical agents, which speciﬁcally inhibit one
of the two zinc catalytic domains of somatic ACE, is of
major importance for the preferential modulation of ACE
proteolytic activity towards a more eﬀective treatment of
hypertensive patients.
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